Emergent Biosolutions Inc Revenue Growth Rates (EBS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Emergent Biosolutions Inc   (NYSE: EBS)
 

EBS's Revenue Growth by Quarter and Year

Emergent Biosolutions Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EBS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 234.30
1st Quarter March 156.10
FY 390.40

EBSs Annual Revenue
Emergent Biosolutions Inc 's Revenue in the fiscal year 2025 $ 742.90 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2024 $ 1,043.60 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2023 $ 1,049.30 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2022 $ 1,117.50 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2021 $ 1,792.70 millions




EBS Revenue second quarter 2026 Y/Y Growth Comment
Emergent Biosolutions Inc achieved in the second quarter 2026, above Company average Revenue rise of 66.29% year on year, to $ 234.30 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Revenue growth. While Emergent Biosolutions Inc ' s Revenue jump of 66.29% ranks overall at the positon no. 3239 in the second quarter 2026.


EBS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -23.63 % -29.41 % -16.47 %
3rd Quarter September - -21.34 % 8.61 % 12.71 %
2nd Quarter June 66.29 % -44.68 % -24.62 % 39.23 %
1st Quarter March -29.75 % -26.03 % 81.95 % -46.31 %
FY   - -28.81 % -0.54 % -

Financial Statements
Emergent Biosolutions Inc 's second quarter 2026 Revenue $ 234.30 millions EBS's Income Statement
Emergent Biosolutions Inc 's second quarter 2025 Revenue $ 140.90 millions Quarterly EBS's Income Statement


EBS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -35.66 % -33.73 % 1.96 %
3rd Quarter September - 64.02 % 15.35 % -19.95 %
2nd Quarter June 50.1 % -36.59 % -15.21 % 104.66 %
1st Quarter March 4.98 % 14.12 % 8.92 % -50 %
FY (Year on Year)   - -28.81 % -0.54 % -


Back to EBS Growth rate Comparisons >> Back to EBS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #138
Healthcare Sector #431
Overall #3239

Revenue Y/Y Growth Statistics
High Average Low
53.98 % 10.53 % -44.65 %
(Mar 31 2021)   (Mar 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #138
Healthcare Sector #431
Overall #3239
Revenue Y/Y Growth Statistics
High Average Low
53.98 % 10.53 % -44.65 %
(Mar 31 2021)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Emergent Biosolutions Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
375.59 % 18.2 % -64.76 %
(Jun 30 2011)  


EBS's II. Quarter Q/Q Revenue Comment
Emergent Biosolutions Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 50.1%, to $ 234.30 millions, from $156.10 millions in the first quarter.
EBS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Emergent Biosolutions Inc 's Revenue growth quarter on quarter, overall rank is 242.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #242
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #242
Revenue Q/Q Growth Statistics
High Average Low
375.59 % 18.2 % -64.76 %
(Jun 30 2011)  


EBS's II. Quarter Q/Q Revenue Comment
Emergent Biosolutions Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 50.1%, to $ 234.30 millions, from $156.10 millions in the first quarter.
EBS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Emergent Biosolutions Inc 's Revenue growth quarter on quarter, overall rank is 242.


Emergent Biosolutions Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 770.20 $ 676.80 $ 742.90 $ 788.90 $ 851.60
Y / Y Revenue Growth (TTM) -9.56 % -29.89 % -28.81 % -29.86 % -22.68 %
Year on Year Revenue Growth Overall Ranking # 3421 # 1183 # 1552 # 1807 # 1267
Seqeuential Revenue Change (TTM) 13.8 % -8.9 % -5.83 % -7.36 % -11.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 3239 # 1111 # 1842 # 1812 # 2569


Cumulative Revenue growth Comment
Emergent Biosolutions Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Emergent Biosolutions Inc 's annual Revenue fall would be -9.56% year on year to $770 millions.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1183 to 3421.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 460
Overall # 3421

Revenue TTM Y/Y Growth Statistics
High Average Low
53.98 %
 10.53 %
-44.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 431
S&P 500 # 3239
Cumulative Revenue growth Comment
Emergent Biosolutions Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Emergent Biosolutions Inc 's annual Revenue drop would be -9.56% year on year to $770 millions.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1183 to 3421.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 460
Overall # 3421

Revenue TTM Y/Y Growth Statistics
High Average Low
53.98 %
10.53 %
-44.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 431
S&P 500 # 3239




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EBS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions


About Emergent Biosolutions Inc Revenue Growth Rates (EBS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Emergent Biosolutions Inc (CIK 1367644).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001367644-26-000082
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Emergent Biosolutions Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.